Avelumab binds PD-L1 on target cells and, via its IgG1 Fc, engages Fc-gamma receptors (e.g., CD16) on NK cells to trigger ADCC (and phagocytosis), directly killing PD-L1–expressing cells; it also blocks PD-1/PD-L1 to restore T-cell cytotoxicity.